Previous 10 | Next 10 |
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results - Full year 2021 total revenues grew to $268.7 million, an 8% increase compared to 2020 - Full year 2022 total revenues expected to be between $240 million and $280 million - End of year 20...
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022 Conference Call and Webcast to Follow PR Newswire WASHINGTON , Feb. 17, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today...
Gainers: Alnylam Pharmaceuticals (NASDAQ:ALNY) +12%. ImmunityBio (NASDAQ:IBRX) +6%. Ortho Clinical Diagnostics Holdings (NASDAQ:OCDX) +5%. Qorvo (NASDAQ:QRVO) +5%. Vanda Pharmaceuticals (NASDAQ:VNDA) +4%. Losers: COMPASS Pathways P(NASDAQ:CMPS) +-5%. GreenSky (NASD...
Gainers: TDCX (NYSE:TDCX) +16%. ALJ Regional Holdings (NASDAQ:ALJJ) +8%. Nxt-ID (NASDAQ:NXTD) +8%. Microvast Holdings (NASDAQ:MVST) +7%. Archer Aviation (NYSE:ACHR) +7%. Losers: SkyWest (NASDAQ:SKYW) -21%. GrafTech International (NYSE:EAF) -9%. Alpine 4 Holdings (NASDAQ:AL...
Gainers: Snap (NYSE:SNAP) +52%. Bill.com Holdings (NYSE:BILL) +31%. Indonesia Energy Corporation (NYSE:INDO) +28%. eGain (NASDAQ:EGAN) +22%. Sphere (NASDAQ:ANY) +21%. Standard Lithium (NYSE:SLI) +17%. Aurora Innovation (NASDAQ:AUR) +17%. Unity Software (NYSE:U) +17%. Astria Therapeutics (NASD...
Gainers: IRadimed IRMD +8%. Meridian Bioscience VIVO +8%. Biofrontera (NASDAQ:BFRI) +6%. Inspira Technologies Oxy (NASDAQ:IINN) +6%. Taysha Gene Therapies (NASDAQ:TSHA) +5%. Losers: Lannett Company (NYSE:LCI) -24%. Vanda Pharmaceuticals (NASDAQ:VNDA) -22%. E...
Vanda Pharmaceuticals' (NASDAQ:VNDA) medicine tradipitant failed to beat placebo in a phase 3 trial to treat symptoms of gastroparesis. The study, dubbed VP-VLY-686-3303, did not meet its main goal of showing a difference between the drug and placebo in changing the s...
Vanda Pharmaceuticals Reports Results from the Phase III Study of Tradipitant in Gastroparesis PR Newswire WASHINGTON , Feb. 4, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced results from its Phase III clinical study, VP-VL...
Vanda Pharmaceuticals Settles HETLIOZ® Patent Litigation with MSN PR Newswire WASHINGTON , Jan. 14, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it has entered into a License Agreement (the License Agreement) wi...
The following slide deck was published by Vanda Pharmaceuticals Inc. in conjunction with this event. For further details see: Vanda Pharmaceuticals (VNDA) Investor Presentation - Slideshow
News, Short Squeeze, Breakout and More Instantly...
Vanda Pharmaceuticals Inc. Company Name:
VNDA Stock Symbol:
NASDAQ Market:
Vanda Pharmaceuticals Inc. Website:
2024-07-17 04:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-11 07:00:07 ET Charles Duncan from Cantor Fitzgerald issued a price target of $11.00 for VNDA on 2024-07-11 06:12:00. The adjusted price target was set to $11.00. At the time of the announcement, VNDA was trading at $5.21. VNDA currently trades -22.96% versus its...
Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex PR Newswire WASHINGTON , July 1, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. District Court for the District of ...